Last reviewed · How we verify
Dysport Injectable Product
Dysport is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
Dysport is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Dysport Injectable Product |
|---|---|
| Also known as | abobotulinumtoxinA, Botulinum toxin A |
| Sponsor | Western University, Canada |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (synaptosomal-associated protein) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Aesthetics |
| Phase | Phase 3 |
Mechanism of action
Dysport contains botulinum toxin type A, which cleaves SNARE proteins required for acetylcholine vesicle fusion and release. This results in temporary denervation and muscle relaxation at the injection site. The effect is localized and reversible, typically lasting 3-4 months before neuromuscular function gradually recovers.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Glabellar lines (wrinkles)
- Hyperhidrosis (excessive sweating)
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness or paralysis (off-target)
- Ptosis (eyelid drooping)
- Antibody formation (neutralizing antibodies)
Key clinical trials
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity (PHASE3)
- A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A (PHASE4)
- Botulinum Toxin Versus Platelet Rich Fibrin for TMJ Internal Derangement (NA)
- A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) (PHASE3)
- Exercise to Improve Sleep and Quality of Life in Stroke Patients Receiving Botulinum Toxin Treatment (NA)
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- OnabotulinumtoxinA for Trigeminal Neuralgia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |